Sanofi, Regeneron gets USFDA approval for cholesterol drug Praluent

The USFDA's decision will allow the Praluent, developed along with Sanofi SA, to be prescribed in reducing the overall risk of major adverse cardiovascular events (MACE).

U.S: The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent, as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Read Also: USFDA approves use of Regeneron, Sanofi eczema drug Dupixent in adolescents

The FDA's decision will allow the drug, developed along with Sanofi SA, to be prescribed in reducing the overall risk of major adverse cardiovascular events (MACE).

MACE is an umbrella term that includes heart attack, ischemic stroke, death from coronary heart disease and unstable chest pains requiring hospitalization.

Read Also: Sanofi, Regeneron loses patent challenge to Amgen cholesterol drug Repatha